PBH Stock Recent News

PBH's shares rise on the back of its portfolio of consumer brands and focus on core strategies to achieve long-term success.

Investors remain optimistic about Prestige Consumer due to its strong focus on brand building and strategic acquisition.

NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, March 05, 2025 (GLOBE NEWSWIRE) -- Premium Brands Holdings Corporation (“Premium Brands” or the “Company”) (TSX: PBH), a leading producer, marketer and distributor of branded specialty food products, is pleased to announce it has entered into an agreement with a syndicate of underwriters co-led by CIBC Capital Markets, National Bank Financial, BMO Capital Markets and Scotiabank (collectively, the “Underwriters”), pursuant to which the Company will issue on a “bought-deal” basis, subject to regulatory approval, $150,000,000 aggregate principal amount of convertible unsecured subordinated debentures (the “Debentures”) at a price of $1,000 per Debenture (the “Offering”). The Company has also granted the Underwriters an over-allotment option to purchase up to an additional $22,500,000 aggregate principal amount of Debentures, on the same terms, exercisable i

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?

Prestige Consumer Healthcare witnesses continued international growth in the third quarter, banking on strong sales of the Hydralyte brand.

Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q3 2025 Results Conference Call February 6, 2025 8:30 AM ET Company Participants Phil Terpolilli - Vice President, Investor Relations Ron Lombardi - Chairman, President & Chief Executive Officer Christine Sacco - Chief Financial Officer Conference Call Participants Rupesh Parikh - Oppenheimer & Company Susan Anderson - Canaccord Genuity Keith Devas - Jefferies David Shakno - William Blair Linda Bolton Weiser - D. A. Davidson Anthony Lebiedzinski - Sidoti & Company Operator Thank you for standing by, and welcome to Prestige Consumer Healthcare's Third Quarter 2025 Earnings Conference Call.

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.06 per share a year ago.

TARRYTOWN, N.Y., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2024.

Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

PBH sees remarkable gains from long-term brand-building strategies and developing the e-commerce channel.